Yellow Fever Monoclonal Antibody Prevents Vaccine-Induced Viremia in Phase 1 Trial

Investigators used YF17D live virus vaccine as a challenge virus to assess the efficacy of monoclonal antibody in abrogating vaccine-induced viremia.

Yellow fever virus (YFV) outbreaks have expanded in South America and Africa and threaten urban areas infested with YFV-competent mosquitoes. No licensed YFV therapeutics are available. Investigators conducted a manufacturer-supported phase 1 clinical trial of a human IgG1 mononclonal antibody (TY014) developed in Chinese hamster ovary cells. TY014 targets an epitope on the YFV envelope protein. Investigators assessed its efficacy in preventing viremia, which occurs in >80% of recipients of the live YFV vaccine (YF17D). TY014 was administered as intravenous infusion.

In the safety assessment phase, 27 healthy adults received five different doses (maximum, 20 mg/kg) or placebo. No worrisome safety signals were identified. The mean half-life w…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Yellow Fever Monoclonal Antibody Prevents Vaccine-Induced Viremia in Phase 1 Trial

Topics

Reviewing Author